Organization
Inhibrx
5 clinical trials
Clinical trial
Phase 2/3, Randomized Study of OX40 Agonist INBRX-106 With Pembrolizumab vs Pembrolizumab as First Line Treatment for Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1(CPS ≥20)Status: Not yet recruiting, Estimated PCD: 2029-05-01
Clinical trial
This is a Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.Status: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-02-02
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional ChondrosarcomaStatus: Recruiting, Estimated PCD: 2024-12-01